Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris Trichiura

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects aged 16 to 18 years, inclusive~2. Written informed consent/assent signed from parent/guardian~3. Positive for T. trichiura by at least two slides of the quadruple Kato-Katz thick smears and infection intensities of at least 100 eggs per gram of stool (EPG)~4. Agree to comply with study procedures, including provision of two stool samples at the beginning (baseline) and approximately three weeks after treatment (follow-up).~Exclusion Criteria:~1. Presence of acute or uncontrolled systemic illnesses (e.g. severe anemia, infection, clinical malaria) as assessed by a medical doctor, upon initial clinical assessment.~2. Known or reported history of chronic illness such as HIV, acute or chronic hepatitis, cancer, diabetes, chronic heart disease or renal disease.~3. Prior treatment with anthelmintics (eg, diethylcarbamazine \[DEC\], suramin, ivermectin or albendazole) within 4 weeks before planned test article administration.~4. Received any investigational drugs or investigational devices within 4 weeks before administration of test article that may confound safety and/or efficacy assessments.~5. Known or suspected allergy to moxidectin, ivermectin or albendazole or other compounds related to these classes of medication.~6. Pregnant (urine testing) or breastfeeding women

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Moxidectin 8 mg (Type: EXPERIMENTAL): A single tablet of 8 mg of moxidectin
- Moxidectin 8 mg + Albendazole (Type: EXPERIMENTAL): A single tablet of 8 mg of moxidectin plus a single tablet of albendazole (400 mg)
- Moxidectin 16 mg (Type: EXPERIMENTAL): Two tablets of 8 mg of moxidectin ( = 16 mg)
- Moxidectin 16 mg + Albendazole (Type: EXPERIMENTAL): Two tablets of 8 mg of moxidectin ( = 16 mg) plus a single tablet of albendazole (400 mg)
- Moxidectin 24 mg (Type: EXPERIMENTAL): Three tablets of 8 mg of moxidectin ( = 24 mg)
- Moxidectin 24 mg + Albendazole (Type: EXPERIMENTAL): Three tablets of 8 mg of moxidectin ( = 24 mg) plus a single tablet of albendazole (400 mg)
- Placebo (Type: PLACEBO_COMPARATOR): A single tablet of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).